A New King of The GLP-1s Could Be Crowned – Cardiac Wire

A New King of The GLP-1s Could Be Crowned  Cardiac Wire‘Godzilla’ of weight-loss drugs could provide other important health benefits  The GuardianWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s  CNBCLilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes  investor.lilly.comLilly raises diabetes weight-loss bar with amylin-Zepbound combo  Fierce Biotech